Kodama K, et al. - In view of the observation that for patients with advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and HCC refractory to transcatheter arterial chemoembolization (TACE) or with macroscopic vascular invasion (MVI), sorafenib is the standard treatment and in Southeast and East Asian countries, hepatic arterial infusion chemotherapy (HAIC) has been used for advanced HCC, researchers sought for clearer information for choosing appropriately between these therapies. They noted transcatheter arterial chemoembolization refractory status with HAIC and MVI with sorafenib to be associated with poor prognosis. In MVI and non-TACE refractory cases, HAIC was particularly significantly better than sorafenib as primary treatment. Thus they recommend considering these factors in treatment selection.